No difference in immunochemotherapy regimens for follicular lymphoma

Hoping to inch towards a consensus on the best treatment approach or a standard of care for patients with advanced-stage follicular lymphoma, the SWOG cancer research cooperative group and Cancer and Leukemia Group B (CALGB) joined forces to see if among a pair of immunochemotherapy regimens, one was better than the other. They presented an abstract of their findings at the recent ASH conference in San Diego.

The Phase III randomized trial involved 526 patients with previously untreated, advanced stage follicular lymphoma. One arm (N=263) received the current, if unofficial, standard of care, six cycles of R-CHOP, while the other arm (N=263) received six cycles of CHOP followed by radioimmunotherapy in the form of tositumomab / iodine I-131, better known as Bexxar.

Grade 4 hematologic toxicities were fairly equal with 36% experiencing them in the R-CHOP arm and 30% in the CHOP-RIT arm.

Researchers concluded that "no statistically significant differences in progression-free survival (PFS), overall survival (OS), or serious toxicities are yet demonstrable with either regimen administered in this trial. However, PFS and OS are outstanding with either of the two regimens."

In other words, more research will be necessary to determine the benefit, if any, of adding RIT to current chemotherapy for this set of patients.

Source

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin’s Lymphoma.

More Articles

More Articles

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Cancer bracelets are undeniably popular, and if purchased through reliable sources such as major charities, they help contribute to the fight...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer of the b- and t-cell lymphocytes, part of the immune system. They account for the most frequent head and neck malignancies....

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

As a kind of cancer, lymphoma attacks the lymphocytes and lymph nodes that are part of the immune system. Head and neck lymphoma results when...

Some cancers have clear environmental causes. Oral cancer is strongly tied to the use of chewing tobacco, and lung cancer is well-known to be much...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...